Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site
Open Access
- 7 November 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2619
Abstract
Previous infection with Epstein-Barr virus (EBV) is believed to trigger autoimmunity and to drive autoantibody generation as occurring in patients with systemic lupus erythematosus (SLE). Complement C1q and autoantibodies targeting it (anti-C1q) are also considered to be involved in the pathogenesis of SLE, independently of the impact of environmental insults. Still, the circumstances under which these autoantibodies arise remain elusive. By studying a major antigenic site of C1q targeted by anti-C1q (A08), we aimed to determine environmental factors and possible mechanisms leading to the development of anti-C1q. First, we determined antigenic residues of A08 that were critical for the binding of anti-C1q; importantly, we found the binding to depend on amino-acid-identity. Anti-C1q of SLE patients targeting these critical antigenic residues specifically cross-reacted with the EBV-related EBNA-1 (Epstein-Barr virus nuclear antigen 1)-derived peptide EBNA348. In a cohort of 180 SLE patients we confirmed that patients that were seropositive for EBV and recognized the EBNA348 peptide had increased levels of anti-A08 and anti-C1q, respectively. The correlation of anti-EBNA348 with anti-A08 levels was stronger in SLE patients than in matched healthy controls. Finally, EBNA348 peptide-immunization of C1q−/− mice induced the generation of cross-reactive antibodies which recognized both the A08 epitope of C1q and intact C1q. These findings suggest that anti-C1q in SLE patients could be induced by an EBV-derived epitope through molecular mimicry, thereby further supporting the pathogenic role of EBV in the development of SLE. Considering the role of C1q and anti-C1q, modifying the anti-EBV response might be a promising strategy to improve the course of the disease.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
This publication has 47 references indexed in Scilit:
- Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosusArthritis Research & Therapy, 2014
- Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritisBMC Nephrology, 2013
- Mitotic chromosome interactions of Epstein-Barr nuclear antigen 1 (EBNA1) and human EBNA1-binding protein 2 (EBP2)Journal of Cell Science, 2009
- C1q Differentially Modulates Phagocytosis and Cytokine Responses during Ingestion of Apoptotic Cells by Human Monocytes, Macrophages, and Dendritic CellsThe Journal of Immunology, 2009
- Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragmentsJournal of Autoimmunity, 2008
- High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritisNephrology Dialysis Transplantation, 2006
- An altered immune response to Epstein‐Barr nuclear antigen 1 in pediatric systemic lupus erythematosusArthritis & Rheumatism, 2005
- Hydrophobic Amino Acid Residues Are Critical for the Immunodominant Epitope of the Goodpasture AutoantigenJournal of Biological Chemistry, 2001
- Immune Response to Different Sequences of the EBNA I Molecule in Epstein-Barr Virus-Related Disorders and in Autoimmune DiseasesJournal of Autoimmunity, 1994
- THE ÆTIOLOGY OF SYSTEM LUPUS ERYTHEMATOSUSThe Lancet, 1964